Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 2/20 | 0.62 |
| ▸ | COMT | P21964 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TPMT | P51580 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.38 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29493674 | 1.00 | FTO (0.62) | FTOCOMTKMT2AMEN1CTNNB1 | |
| SCHEMBL20100858 | 0.88 | FTO (0.62) | FTOCOMTKMT2AMEN1ABCB1 | |
| SCHEMBL28717463 | 0.85 | FTO (0.83) | FTOCOMTKMT2AMEN1POLB | |
| SCHEMBL20100859 | 0.85 | FTO (0.83) | FTOCOMTKMT2AMEN1POLB | |
| SCHEMBL29493665 | 0.85 | FTO (0.83) | FTOCOMTKMT2AMEN1POLB | |
| SCHEMBL28720678 | 0.82 | FTO (0.63) | FTOCOMTKMT2AMEN1TPMT | |
| SCHEMBL28720676 | 0.82 | FTO (0.63) | FTOCOMTKMT2AMEN1TPMT | |
| SCHEMBL20100828 | 0.81 | COMT (0.72) | FTOCOMTKMT2AMEN1RAB9A | |
| SCHEMBL29493647 | 0.81 | COMT (0.72) | FTOCOMTKMT2AMEN1RAB9A | |
| SCHEMBL28717367 | 0.80 | FTO (0.61) | FTOCOMTKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922316-B | FTO inhibitors | 北京生命科学研究所 | 2022-04-08 | — | — | CN | disclosed |
| EP-3885337-A1 | FTO INHIBITORS | National Institute Of Biological Sciences, Beijing (CN) | 2021-09-29 | — | — | EP | disclosed |
| EP-3303283-B1 | FTO INHIBITORS | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2021-04-21 | — | — | EP | disclosed |
| US-20180118665-A1 | FTO Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118665-A1 | FTO Inhibitors | FTO, ALKBH3, ALKBH1 | FTO 1/4885COMT 9/4885KMT2A 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.